Principal Financial Group Inc Protagonist Therapeutics, Inc Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024
SELL
$24.66 - $34.8 $107,049 - $151,066
-4,341 Reduced 30.21%
10,028 $347,000
Q1 2024

Apr 29, 2024
SELL
$21.79 - $32.15 $1,307 - $1,929
-60 Reduced 0.42%
14,369 $415,000
Q4 2023

Feb 07, 2024
SELL
$14.05 - $23.44 $7,615 - $12,704
-542 Reduced 3.62%
14,429 $330,000
Q3 2023

Nov 02, 2023
BUY
$16.68 - $23.66 $17,814 - $25,268
1,068 Added 7.68%
14,971 $249,000
Q2 2023

Aug 07, 2023
BUY
$18.02 - $29.36 $6,847 - $11,156
380 Added 2.81%
13,903 $384,000
Q1 2023

May 09, 2023
BUY
$10.78 - $25.38 $19,242 - $45,303
1,785 Added 15.21%
13,523 $311,000
Q4 2022

Feb 09, 2023
BUY
$7.36 - $11.17 $10,223 - $15,515
1,389 Added 13.42%
11,738 $128,000
Q3 2022

Nov 09, 2022
BUY
$7.86 - $11.71 $81,343 - $121,186
10,349 New
10,349 $87,000
Q1 2022

May 09, 2022
SELL
$23.34 - $36.08 $177,547 - $274,460
-7,607 Closed
0 $0
Q4 2021

Feb 09, 2022
BUY
$17.63 - $37.1 $134,111 - $282,219
7,607 New
7,607 $260,000
Q3 2021

Nov 09, 2021
SELL
$12.95 - $49.69 $214,193 - $821,872
-16,540 Closed
0 $0
Q2 2021

Aug 10, 2021
BUY
$25.57 - $44.88 $213,867 - $375,376
8,364 Added 102.3%
16,540 $742,000
Q1 2021

May 10, 2021
BUY
$19.02 - $31.15 $155,507 - $254,682
8,176 New
8,176 $212,000

Others Institutions Holding PTGX

# of Institutions
246
Shares Held
56.4M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.02B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email